Outcomes Intelligence
Your Evidence Standard Shouldn’t Be Defined by Spreadsheets and Analysts
Kognitic Outcomes structures published clinical evidence into normalized, comparable benchmarks across endpoints, populations, and treatment settings. The comparison your review committee requires, delivered before they ask for it.
Comparison Attributes | NOVA-LUNG-04 Stage IV NSCLC, EGFR exon 19 del, treatment naive, ECOG 0–1 (n=42) | MERIDIAN-T3 Advanced NSCLC, PD-L1 ≥50%, platinum ineligible, IO naive (n=31) |
|---|---|---|
| Abstract Details | ||
| Arm Type | Experimental | Active Comparator |
| Patient Cohort | Stage IV NSCLC, EGFR exon 19 del, treatment naive, ECOG 0–1 | Advanced NSCLC, PD-L1 ≥50%, platinum ineligible, IO naive |
| Drug Treatment | Velunib + Carboplatin | Axtrelin Monotherapy |
| Company |
Nexagen Therapeutics
|
Zentis Pharma
|
| Indication | Non small Cell Lung Cancer | Non small Cell Lung Cancer |
| Line of Therapy | 1L | 2L |
| Biomarker | EGFR exon 19 | PD-L1 ≥50% |
| Target Enrollment | 48 | 35 |
| Evaluable Patients | 42 | 31 |
| Efficacy Outcomes | ||
|
PFS at 6 months
| 78% | 82% |
|
Median PFS
| 14.2 mo | 16.8 mo |
|
Median Overall Survival
| Not reached | 22.6 mo |
| ORR | Overall Response Rate 67.3% | Overall Response Rate 74.1% |
| DCR | Disease Control Rate 88.4% | Disease Control Rate 90.3% |
| Study Details | ||
| Abstract Number | ESMO-2022-0441 | ASCO-2023-0118 |
| Trial Status | Recruiting | Completed |
| Phase / Status | Phase 2 | Phase 3 |
| Registry ID | NCT04812249 | NCT05091034 |
Partners Powered by Kognitic
Outcomes Intelligence
The Evidence Landscape
Structured Abstracts. Filtered by Target, Modality, Phase & Indication
See the full evidence landscape before you drill into any comparison. Top drugs, target coverage, and treatment modalities, all structured from published abstracts and conference proceedings. The overview that replaces the first two weeks of your competitive analysis.
Evidence Overview — NSCLC
Structured from published abstracts and conference proceedings
Top Drugs by Abstract Volume
Target Distribution
Efficacy Benchmarking
Standard of Care Context for Every Approved Treatment in the Indication
Eligibility criteria, biomarker strategy, randomization arms, primary and secondary endpoints. Every trial was normalized into a comparable schema. The complexity stays. The manual effort disappears.
Approved Treatment Benchmarking
Approved treatments with normalized efficacy endpoints, ready for your comparison
Built for the Evidence That Defines Your Strategy
MEDICAL AFFAIRS
What does the evidence actually show, normalized and in context?
Outcomes eliminates weeks of manual abstract extraction and endpoint reconciliation. Efficacy endpoints, safety signals, and patient cohort details are structured into a single comparable view across studies. Your leadership review starts with the analysis, not the data collection.
COMMERCIAL STRATEGY
Where does your therapy stand against the competition?
Outcomes maps endpoint performance across the competitive landscape. PFS, OS, ORR, and safety profiles are normalized and compared side by side, so your positioning narrative is grounded in structured evidence rather than selective citations.
BUSINESS DEVELOPMENT
Should you pursue this asset?
Outcomes structures published evidence into a normalized benchmark that stress-tests clinical claims across biomarker segments, lines of therapy, and treatment settings. Walk into diligence with a comparative view that holds up under scrutiny.
See Your Evidence
Through Outcomes
Outcomes Intelligence is available to select partners in early access. Our team will walk you through a live evidence comparison in your therapeutic area, structured from published endpoints.